Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002994 · ClinicalTrials.gov registry record · Phase 1
Interleukin-2 Plus Monoclonal Antibody Therapy in Treating Patients With Solid Tumors
A Phase 1 study, sponsored by Alliance for Clinical Trials in Oncology.
- Completed
- Registry status
- Phase 1
- Development phase
- 355
- Enrollment target
NCT00002994 is a Phase 1 study that has completed, run by Alliance for Clinical Trials in Oncology. The registered enrollment target is 355 participants.
The verdict
NCT00002994, a Phase 1 study, has completed, sponsored by Alliance for Clinical Trials in Oncology.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 355 participants
- Enrollment target
Study Summary
RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill solid tumor cells. Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. PURPOSE: Pilot study to examine the effectiveness of interleukin-2 plus monoclonal antibody in treating patients who have solid tumors.
Interventions
- BIOLOGICAL interleukin 2
- BIOLOGICAL rhuMAb
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 355 participants |
| Start Date | 1997-07 |
| Est. Completion | 2002-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002994
The ClinicalTrials.gov registry entry for NCT00002994 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 355 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alliance for Clinical Trials in Oncology, which has 446 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which interleukin 2 is the first listed.
NCT00002994 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00002994 about?
NCT00002994 is a clinical study titled "Interleukin-2 Plus Monoclonal Antibody Therapy in Treating Patients With Solid Tumors". RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill solid tumor cells. Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. PURPOSE: Pilot study to examine the effectiveness of interleukin...
What is the current status of trial NCT00002994?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 355 participants. The study started on 1997-07. Estimated completion is 2002-04.
What interventions are being tested in trial NCT00002994?
The interventions under investigation include: interleukin 2 (BIOLOGICAL), rhuMAb (BIOLOGICAL).
Who is sponsoring clinical trial NCT00002994?
This trial is sponsored by Alliance for Clinical Trials in Oncology, which has 446 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.